Foghorn Therapeutics Inc.

10/10/2024 | Press release | Distributed by Public on 10/10/2024 06:49

Foghorn Therapeutics Announces First Patient Dosed with First in Class Oral SMARCA2 Selective Inhibitor FHD 909 in a Phase 1 Trial for SMARCA4 Mutated Solid Tumors

Read this content
Click here to read the original version at the source's official website. The text of this article is not available at the moment.